FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068223142> ?p ?o ?g. }

• W2068223142 endingPage "649" @default.
• W2068223142 startingPage "641" @default.
• W2068223142 abstract "To evaluate the effect of botulinum neurotoxin type-A (BoNT-A) on chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) refractory to medical therapy.Between November 2011 and January 2013, 60 men aged ≥18 years with CP/CPPS, and with National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) scores ≥10 and pain subscale scores ≥8, who were refractory to 4-6 weeks' medical therapy, underwent transurethral intraprostatic injection of BoNT-A or normal saline in a prospective pilot double-blind randomized study. The patients' NIH-CPSI total and subscale scores, American Urological Association (AUA)-symptom score (SS), visual analogue scale (VAS) and quality of life (QoL) scores and frequencies of diurnal and nocturnal urination were evaluated and compared at baseline and at 1, 3 and 6 months after injection and also were compared between the two groups.A total of 60 consecutive patients were randomized to a BoNT-A (treatment) or normal saline (placebo) group. In the treatment group at the 1-, 3- and 6-month evaluation the NIH-CPSI total and subscale scores, and the AUA-SS, VAS and QoL scores, along with frequencies of diurnal and nocturnal urinations, had significantly improved compared with baseline values (P < 0.05). By contrast, in the placebo group, none of these values showed improvement and the values were significantly different from those in the treatment group. Although the differences between the two groups in AUA-SS and frequencies of nocturnal urination were not significant at 1-month follow-up, repeated-measure analysis showed significant improvement in each of these values over the entire follow-up period in the treatment group. The most prominent improvement was related to the pain subscale score, which decreased by 64.76, 75.63 and 79.97% at 1, 3 and 6 months after treatment compared with baseline, followed by the VAS score, which decreased by 62.3, 72.4 and 82.1% at each follow-up, respectively. Only two patients developed mild transient gross haematuria, which was managed conservatively.Transurethral intraprostatic BoNT-A injection maybe an effective therapeutic option in patients with CP/CPPS as it reduces pain and improves QoL." @default.
• W2068223142 created "2016-06-24" @default.
• W2068223142 creator A5013400763 @default.
• W2068223142 creator A5027791867 @default.
• W2068223142 creator A5050363333 @default.
• W2068223142 creator A5064467306 @default.
• W2068223142 date "2015-05-25" @default.
• W2068223142 modified "2023-10-05" @default.
• W2068223142 title "Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double-blind and randomized placebo-controlled study" @default.
• W2068223142 cites W1973214716 @default.
• W2068223142 cites W1978505438 @default.
• W2068223142 cites W1979056247 @default.
• W2068223142 cites W1981985054 @default.
• W2068223142 cites W1982920003 @default.
• W2068223142 cites W1986309799 @default.
• W2068223142 cites W1997517088 @default.
• W2068223142 cites W2010061032 @default.
• W2068223142 cites W2010714442 @default.
• W2068223142 cites W2019412665 @default.
• W2068223142 cites W2026467462 @default.
• W2068223142 cites W2026741721 @default.
• W2068223142 cites W2032419998 @default.
• W2068223142 cites W2041376248 @default.
• W2068223142 cites W2046446670 @default.
• W2068223142 cites W2049731576 @default.
• W2068223142 cites W2052186398 @default.
• W2068223142 cites W2054112193 @default.
• W2068223142 cites W2061084999 @default.
• W2068223142 cites W2063311455 @default.
• W2068223142 cites W2069548254 @default.
• W2068223142 cites W2069885571 @default.
• W2068223142 cites W2082083251 @default.
• W2068223142 cites W2089738403 @default.
• W2068223142 cites W2093424875 @default.
• W2068223142 cites W2152368658 @default.
• W2068223142 cites W2794130438 @default.
• W2068223142 cites W2993539218 @default.
• W2068223142 cites W4249980040 @default.
• W2068223142 doi "https://doi.org/10.1111/bju.12951" @default.
• W2068223142 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25307409" @default.
• W2068223142 hasPublicationYear "2015" @default.
• W2068223142 type Work @default.
• W2068223142 sameAs 2068223142 @default.
• W2068223142 citedByCount "46" @default.
• W2068223142 countsByYear W20682231422015 @default.
• W2068223142 countsByYear W20682231422016 @default.
• W2068223142 countsByYear W20682231422017 @default.
• W2068223142 countsByYear W20682231422018 @default.
• W2068223142 countsByYear W20682231422019 @default.
• W2068223142 countsByYear W20682231422020 @default.
• W2068223142 countsByYear W20682231422021 @default.
• W2068223142 countsByYear W20682231422022 @default.
• W2068223142 countsByYear W20682231422023 @default.
• W2068223142 crossrefType "journal-article" @default.
• W2068223142 hasAuthorship W2068223142A5013400763 @default.
• W2068223142 hasAuthorship W2068223142A5027791867 @default.
• W2068223142 hasAuthorship W2068223142A5050363333 @default.
• W2068223142 hasAuthorship W2068223142A5064467306 @default.
• W2068223142 hasConcept C121608353 @default.
• W2068223142 hasConcept C126322002 @default.
• W2068223142 hasConcept C126894567 @default.
• W2068223142 hasConcept C141071460 @default.
• W2068223142 hasConcept C14184104 @default.
• W2068223142 hasConcept C142724271 @default.
• W2068223142 hasConcept C159110408 @default.
• W2068223142 hasConcept C168563851 @default.
• W2068223142 hasConcept C175768497 @default.
• W2068223142 hasConcept C188816634 @default.
• W2068223142 hasConcept C204787440 @default.
• W2068223142 hasConcept C27081682 @default.
• W2068223142 hasConcept C2776235491 @default.
• W2068223142 hasConcept C2776362571 @default.
• W2068223142 hasConcept C2777397205 @default.
• W2068223142 hasConcept C2779951463 @default.
• W2068223142 hasConcept C2780136519 @default.
• W2068223142 hasConcept C2780524745 @default.
• W2068223142 hasConcept C42219234 @default.
• W2068223142 hasConcept C71924100 @default.
• W2068223142 hasConcept C77411442 @default.
• W2068223142 hasConceptScore W2068223142C121608353 @default.
• W2068223142 hasConceptScore W2068223142C126322002 @default.
• W2068223142 hasConceptScore W2068223142C126894567 @default.
• W2068223142 hasConceptScore W2068223142C141071460 @default.
• W2068223142 hasConceptScore W2068223142C14184104 @default.
• W2068223142 hasConceptScore W2068223142C142724271 @default.
• W2068223142 hasConceptScore W2068223142C159110408 @default.
• W2068223142 hasConceptScore W2068223142C168563851 @default.
• W2068223142 hasConceptScore W2068223142C175768497 @default.
• W2068223142 hasConceptScore W2068223142C188816634 @default.
• W2068223142 hasConceptScore W2068223142C204787440 @default.
• W2068223142 hasConceptScore W2068223142C27081682 @default.
• W2068223142 hasConceptScore W2068223142C2776235491 @default.
• W2068223142 hasConceptScore W2068223142C2776362571 @default.
• W2068223142 hasConceptScore W2068223142C2777397205 @default.
• W2068223142 hasConceptScore W2068223142C2779951463 @default.
• W2068223142 hasConceptScore W2068223142C2780136519 @default.
• W2068223142 hasConceptScore W2068223142C2780524745 @default.
• W2068223142 hasConceptScore W2068223142C42219234 @default.

• next